Albireo Dashes Into PFIC Market As FDA, EMA Approve Bylvay

The company anticipates an addressable global market for progressive familial intrahepatic cholestasis of 2,500 patients, with initial plans to focus on around 100 physicians at 60 centers.

liver
Albireo is aiming to launch Bylvay immediately in the US, targeting around 100 physicians at 60 centers • Source: Shutterstock

More from Rare Diseases

More from Scrip